Q - LifeMD,
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
LFMD$1.74-16.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
CONDENSED Consolidated STATEMENTS of CHANGES IN STOCKHOLDERS’ EQUITY (Deficit)
| LifeMD, Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Treasury · Non- controlling | ||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stock | Total | Interest | Total | |
| Balance, January 1, 2024 | 1,400,000 | $140 | 38,358,641 | $383,586 | $217,550,583 | $(214,265,236) | $(163,701) | $3,505,372 | $2,060,787 | $5,566,159 |
| Stock compensation expense | - | - | 943,375 | 9,434 | 2,534,996 | - | - | 2,544,430 | - | 2,544,430 |
| Stock issued for noncontingent consideration payment | - | - | 95,821 | 958 | 641,042 | - | - | 642,000 | - | 642,000 |
| Exercise of stock options | - | - | 1,250 | 13 | 7,800 | - | - | 7,813 | - | 7,813 |
| Cashless exercise of warrants | - | - | 1,268,476 | 12,685 | (12,685) | - | - | - | - | - |
| Cashless exercise of stock options | - | - | 64,113 | 641 | (641) | - | - | - | - | - |
| Series A Preferred Stock Dividend | - | - | - | - | - | (776,563) | - | (776,563) | - | (776,563) |
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | (36,000) | (36,000) |
| Net (loss) income | - | - | - | - | - | (6,768,355) | - | (6,768,355) | 119,432 | (6,648,923) |
| Balance, March 31, 2024 | 1,400,000 | $140 | 40,731,676 | $407,317 | $220,721,095 | $(221,810,154) | $(163,701) | $(845,303) | $2,144,219 | $1,298,916 |
| Stock compensation expense | - | - | 142,250 | 1,423 | 4,189,753 | - | - | 4,191,176 | - | 4,191,176 |
| Exercise of stock options | - | - | 75,000 | 750 | 99,250 | - | - | 100,000 | - | 100,000 |
| Cashless exercise of stock options | - | - | 448,664 | 4,486 | (4,486) | - | - | - | - | - |
| Cashless exercise of warrants | - | - | 361,982 | 3,620 | (3,620) | - | - | - | - | - |
| Series A Preferred Stock Dividend | - | - | - | - | - | (776,562) | - | (776,562) | - | (776,562) |
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | (36,000) | (36,000) |
| Net (loss) income | - | - | - | - | - | (6,875,640) | - | (6,875,640) | 38,606 | (6,837,034) |
| Balance, June 30, 2024 | 1,400,000 | $140 | 41,759,572 | $417,596 | $225,001,992 | $(229,462,356) | $(163,701) | $(4,206,329) | $2,146,825 | $(2,059,504) |
| LifeMD, Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Treasury · Non- controlling | ||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stock | Total | Interest | Total | |
| Balance, January 1, 2025 | 1,400,000 | $140 | 42,293,907 | $422,939 | $230,508,339 | $(236,253,218) | $(163,701) | $(5,485,501) | $1,440,133 | $(4,045,368) |
| Stock compensation expense | - | - | 1,282,654 | 12,827 | 2,535,701 | - | - | 2,548,528 | - | 2,548,528 |
| Cashless exercise of stock options | - | - | 56,139 | 561 | (561) | - | - | - | - | - |
| Series A Preferred Stock Dividend | - | - | - | - | - | (776,563) | - | (776,563) | - | (776,563) |
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | (36,000) | (36,000) |
| Net income | - | - | - | - | - | 1,384,804 | - | 1,384,804 | 531,845 | 1,916,649 |
| Balance, March 31, 2025 | 1,400,000 | $140 | 43,632,700 | $436,327 | $233,043,479 | $(235,644,977) | $(163,701) | $(2,328,732) | $1,935,978 | $(392,754) |
| Stock compensation expense | - | - | 346,250 | 3,463 | 2,091,151 | - | - | 2,094,614 | - | 2,094,614 |
| Cashless exercise of stock options | - | - | 50,119 | 501 | (501) | - | - | - | - | - |
| Cashless exercise of warrants | - | - | 390,115 | 3,901 | (3,901) | - | - | - | - | - |
| Stock issued for debt conversion | - | - | 672,042 | 6,720 | 993,280 | - | - | 1,000,000 | - | 1,000,000 |
| Stock issued for asset acquisition | - | - | 50,000 | 500 | 302,500 | - | - | 303,000 | - | 303,000 |
| Series A Preferred Stock Dividend | - | - | - | - | - | (776,562) | - | (776,562) | - | (776,562) |
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | (276,119) | (276,119) |
| Net (loss) income | - | - | - | - | - | (2,074,874) | - | (2,074,874) | 505,075 | (1,569,799) |
| Balance, June 30, 2025 | 1,400,000 | $140 | 45,141,226 | $451,412 | $236,426,008 | $(238,496,413) | $(163,701) | $(1,782,554) | $2,164,934 | $382,380 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.